Sarepta Therapeutics
SRPT
454 hedge funds and large institutions have $12.1B invested in Sarepta Therapeutics in 2020 Q4 according to their latest regulatory filings, with 95 funds opening new positions, 126 increasing their positions, 160 reducing their positions, and 40 closing their positions.
138% more first-time investments, than exits
New positions opened: 95 | Existing positions closed: 40
20% more capital invested
Capital invested by funds: $10.1B → $12.1B (+$2.01B)
13% more funds holding
Funds holding: 403 → 454 (+51)
5% less call options, than puts
Call options by funds: $683M | Put options by funds: $719M
1.56% less ownership
Funds ownership: 91.34% → 89.78% (-1.6%)
21% less repeat investments, than reductions
Existing positions increased: 126 | Existing positions reduced: 160
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$152M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$51.3M |
| 3 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
+$39M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$36M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$32.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$132M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$81.5M |
| 3 |
FAM
Fred Alger Management
New York
|
-$60.1M |
| 4 |
JP Morgan Chase
New York
|
-$55.1M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$45.8M |
SRPT Hedge Fund Activity: Q4 2020 in Review
454 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q4 2020, worth a combined $12.1B — up 20% from $10.1B a quarter earlier.
Buyers outnumbered sellers: 95 funds opened new SRPT positions and 40 closed out — a net gain of 55 holders — while 126 added to existing stakes and 160 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $152M. The largest seller was Sands Capital Management, cutting an estimated $132M.
- 454 institutional investors held Sarepta Therapeutics (SRPT) as of Q4 2020, up from 403 in Q3 2020.
- Funds reported $12.1B of Sarepta Therapeutics stock for Q4 2020, up 20% quarter-over-quarter.
- 95 funds opened new Sarepta Therapeutics positions in Q4 2020 and 40 closed out, a net change of +55 holders.
- The largest Sarepta Therapeutics buyer in Q4 2020 was Capital Research Global Investors, an estimated $152M added.
- The largest Sarepta Therapeutics seller in Q4 2020 was Sands Capital Management, an estimated $132M sold.
Based on aggregated 13F filings for Q4 2020.